{"id":"aspirin-81-enteric-coated-tablet-daily","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Gastrointestinal bleeding"},{"rate":"5-10","effect":"Dyspepsia"},{"rate":"2-5","effect":"Nausea"},{"rate":"<1","effect":"Hemorrhagic stroke"},{"rate":"<1","effect":"Allergic reactions"}]},"_chembl":{"chemblId":"CHEMBL25","moleculeType":"Small molecule","molecularWeight":"180.16"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aspirin acetylates serine residues on COX-1 and COX-2 enzymes, permanently blocking their catalytic activity. This prevents the synthesis of thromboxane A2 in platelets, which is a key mediator of platelet activation and clot formation. At low doses (81 mg), aspirin preferentially affects platelet function, making it effective for antiplatelet therapy without significantly affecting other prostaglandin-dependent processes.","oneSentence":"Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of thromboxane A2 and preventing platelet aggregation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:18:55.644Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cardiovascular disease prevention (secondary prevention post-myocardial infarction or stroke)"},{"name":"Acute coronary syndrome"},{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT04295486","phase":"PHASE2","title":"Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty","status":"RECRUITING","sponsor":"University of Miami","startDate":"2021-03-01","conditions":"Venous Thromboembolism","enrollment":5478},{"nctId":"NCT03417388","phase":"PHASE4","title":"Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2018-02-09","conditions":"Coronary Artery Disease","enrollment":2476},{"nctId":"NCT06935994","phase":"PHASE2","title":"Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease","status":"RECRUITING","sponsor":"Taichung Veterans General Hospital","startDate":"2025-05-05","conditions":"Metabolic Dysfunction Associated Steatotic Liver Disease","enrollment":120},{"nctId":"NCT06541691","phase":"NA","title":"Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic Disease","status":"RECRUITING","sponsor":"Rajaie Cardiovascular Medical and Research Center","startDate":"2024-03-06","conditions":"Atherosclerotic Cardiovascular Disease, Coronary Artery Disease, Ischemic Heart Disease","enrollment":3000},{"nctId":"NCT04158830","phase":"PHASE4","title":"Aspirin (ASA) Therapy and Preeclampsia Prevention","status":"WITHDRAWN","sponsor":"University of Tennessee","startDate":"2020-06-01","conditions":"Preeclampsia","enrollment":""},{"nctId":"NCT02062255","phase":"EARLY_PHASE1","title":"Impact of COX2 on Sera Biomarkers From Obese Subjects","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2013-10","conditions":"Breast Cancer Survivors","enrollment":126}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aspirin"],"phase":"marketed","status":"active","brandName":"Aspirin 81 enteric coated tablet daily","genericName":"Aspirin 81 enteric coated tablet daily","companyName":"University of Florida","companyId":"university-of-florida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of thromboxane A2 and preventing platelet aggregation. Used for Cardiovascular disease prevention (secondary prevention post-myocardial infarction or stroke), Acute coronary syndrome, Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}